letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...8182838485868788899091...100101»
  • ||||||||||  letrozole / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. (Pubmed Central) -  Sep 18, 2017   
    She received adjuvant radiation therapy and initiated letrozole, with excellent compliance during the interval 6-year period...The patient reported mild pain that was adequately controlled with over-the-counter anti-inflammatory medications. She has remained active with an excellent performance status.
  • ||||||||||  letrozole / Generic mfg., nintedanib / Generic mfg.
    Trial primary completion date:  Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics (clinicaltrials.gov) -  Sep 14, 2017   
    P1,  N=22, Recruiting, 
    The addition of palbociclib to letrozole was associated with increased efficacy without negatively impacting pain severity or pain interference with daily activities. Trial primary completion date: Jul 2017 --> Oct 2017
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. (Pubmed Central) -  Aug 30, 2017   
    Using a TN experimental metastases model, we demonstrate that ovariectomy decreased the frequency of magnetic resonance imaging-detectable lesions by 56% as compared with estrogen supplementation, and that the combination of ovariectomy and letrozole further reduced the frequency of large lesions to 14.4% of the estrogen control...Thus, S100A4 is one effector of the paracrine action of E2 in brain metastatic cells. These studies provide a novel mechanism by which estrogens, acting through ER+ astrocytes in the brain microenvironment, can promote BM of TN breast cancers, and suggests existing endocrine agents may provide some clinical benefit towards reducing and managing BM.Oncogene advance online publication, 28 September 2015; doi:10.1038/onc.2015.353.
  • ||||||||||  Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
    Enrollment closed, Trial primary completion date, Metastases:  CHEOPS: Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. (clinicaltrials.gov) -  Aug 24, 2017   
    P2,  N=120, Active, not recruiting, 
    These studies provide a novel mechanism by which estrogens, acting through ER+ astrocytes in the brain microenvironment, can promote BM of TN breast cancers, and suggests existing endocrine agents may provide some clinical benefit towards reducing and managing BM.Oncogene advance online publication, 28 September 2015; doi:10.1038/onc.2015.353. Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Jan 2018
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
    Trial primary completion date, Metastases:  Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (clinicaltrials.gov) -  Aug 9, 2017   
    P2,  N=74, Active, not recruiting, 
    Initiation date: Oct 2010 --> Jan 2011 Trial primary completion date: Dec 2016 --> Jun 2017
  • ||||||||||  letrozole / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date:  Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma (clinicaltrials.gov) -  Jul 28, 2017   
    P2,  N=9, Terminated, 
    Research on predictive markers will be required to clarify the role of bevacizumab in this setting. N=80 --> 9 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2017; Low accrual
  • ||||||||||  letrozole / Generic mfg.
    Phase classification, Enrollment change, Trial initiation date, Trial primary completion date:  Letrozole Treatment in Normal and GnRH Deficient Women (clinicaltrials.gov) -  Jul 27, 2017   
    P1/2,  N=15, Active, not recruiting, 
    Trial primary completion date: Apr 2017 --> Aug 2017 Phase classification: P2/3 --> P1/2 | N=70 --> 15 | Initiation date: Jul 2004 --> Jan 2004 | Trial primary completion date: Dec 2011 --> Jun 2009
  • ||||||||||  letrozole / Generic mfg.
    Enrollment open, Combination therapy:  Study of Letrozole in Recurrent Gliomas (clinicaltrials.gov) -  Jul 23, 2017   
    P0/1,  N=12, Recruiting, 
    Phase classification: P2/3 --> P1/2 | N=70 --> 15 | Initiation date: Jul 2004 --> Jan 2004 | Trial primary completion date: Dec 2011 --> Jun 2009 Not yet recruiting --> Recruiting
  • ||||||||||  letrozole / Generic mfg.
    Trial primary completion date:  PLUM: Pilot of Letrozole for Uterine Myomas (clinicaltrials.gov) -  Jul 16, 2017   
    P4,  N=20, Active, not recruiting, 
    N=1050 --> 1294 | Trial primary completion date: Mar 2016 --> Mar 2018 Trial primary completion date: Jun 2017 --> Dec 2017
  • ||||||||||  letrozole / Generic mfg.
    Trial primary completion date:  DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) -  Jul 13, 2017   
    P2,  N=108, Active, not recruiting, 
    PDX tumor models can be generated from biopsies of ovarian tumors. Trial primary completion date: Jun 2017 --> Aug 2016
  • ||||||||||  letrozole / Generic mfg.
    Trial primary completion date, IO biomarker:  Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. (clinicaltrials.gov) -  Jul 5, 2017   
    P=N/A,  N=18, Active, not recruiting, 
    The risk of OFR during treatment with AIs in amenorrheic women in their 40s is high, and AI therapy should be avoided in these patients. Trial primary completion date: Jun 2017 --> Dec 2017